4 transcripts
NTRA
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
represent execution above our prior expectations.
While the ASPs improve, we continue to benefit from the efforts of our R&D team to reduce our cost
NTRA
Earnings call transcript
NASDAQ
2024 Q1
9 May 24
increased cost in Signatera COGS, but we are already below our goal of $450 based on the scaling benefits that we expect to stay there for the rest
NTRA
Earnings call transcript
NASDAQ
2023 Q4
28 Feb 24
believe could benefit patients in the years to come. We can do this because our core fundamentals are so strong. We're in large, expanding markets, our
NTRA
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
weakness, heart issues and breathing difficulties. One of the most important benefits of carrier screening is early diagnosis for conditions like DMD so
- Prev
- 1
- Next